Only one analyst firm currently publishes a price target for IRIX, so a true multi-analyst consensus cannot be calculated. Alliance Global Partners' Scott Henry initiated coverage on February 5, 2026 with a Buy rating and a $3.00 target, then lowered it to $2.75 on May 20, 2026 after the company's most recent results, describing the 2026 outlook as "flattish." The $2.75 figure was reiterated in August 2026. Because a single analyst cannot form a meaningful average, this article treats $2.75 as a publicly discussed price objective rather than a consensus, with the analyst's own target history effectively spanning $2.75 to $3.00.
The latest verified price is about $0.69, within a 52-week range of roughly $0.61 to $1.65. Reaching $2.75 would require upside of approximately 300% — a very large move, nearly four times the current price and well above the stock's 52-week high. The fundamentals show a company under pressure: trailing revenue of about $51.6 million, a net loss of roughly $3.6 million, EPS (earnings per share) of about -$0.20, and cash of approximately $4.7 million. A move toward $2.75 would likely depend on a return to revenue growth, meaningful loss reduction, and a substantial re-rating of the stock, rather than incremental improvement alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The 52-week high near $1.65 is the most relevant overhead level and sits far below the $2.75 target, meaning the stock would need to clear that prior peak first and sustain a breakout with no recent trading history to anchor it. The round $1.00 level represents an early psychological hurdle, while the 52-week low near $0.61 marks the key downside reference. With the price near the bottom of its range, the longer-term trend structure remains firmly lower.
Analyst price targets generally reflect a roughly 12-month research horizon, and the single target here appears consistent with that convention. Investors should monitor quarterly revenue, particularly for the Cyclo G6 and PASCAL product lines, changes to loss guidance, cash burn and any financing activity, and whether additional analysts initiate coverage — which would provide a broader, more reliable picture than one firm's estimate. From what I see, tracking these elements closely helps clarify whether the setup remains viable.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, the tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. For investors tracking volatile small-cap names like IRIX, automated signals can offer a timely complement to fundamental analysis. In my view, this kind of AI assistance has become a useful part of staying on top of names that move quickly on limited coverage.
The $2.75 figure is a genuine, published price objective, but it reflects a single analyst's view rather than a consensus, and it demands a roughly 300% move from the current price near $0.69. The bullish case rests on renewed growth in the Cyclo G6 and PASCAL laser franchises and a sharp narrowing of losses, while the bearish case points to flat revenue, wider-than-expected losses, and a constrained cash position. Given the gap between the current price and the target, the outcome hinges less on near-term earnings than on a durable return to growth and a re-rating of the stock. Investors should watch upcoming results, analyst revisions, and any new coverage rather than treat $2.75 as an expectation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for IRIX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of light-based medical systems and delivery devices
Industry MedicalNursingServices